News

Nektar Therapeutics Successfully Closes $115 Million Public Offering San Francisco, CA – July 2, 2025 – Nektar Therapeutics (NASDAQ: NKTR), a biopharmaceutical company dedicated to developing innovative medicines for patients suffering from cancer and autoimmune diseases, today announced the successful closing of its previously announced public offering of common stock. The offering, which included the … Read more

INOVIO Announces Proposed Public Offering to Fuel Growth and Innovation PLYMOUTH MEETING, PA – July 2, 2025 – INOVIO, a biotechnology company dedicated to developing DNA-based vaccines and therapies, announced today its intention to conduct a proposed public offering of its common stock. This strategic move aims to bolster the company’s financial position and support … Read more

TRICARE Announces Temporary Payment Suspension for Certain Services FOR IMMEDIATE RELEASE [City, State] – July 2, 2025 – TRICARE, the healthcare program for uniformed service members, retirees, and their families, has announced a temporary suspension of payments for a specific category of services. This update, released by PR Newswire Healthring, aims to ensure the continued … Read more

Sleep Apnea Market Poised for Significant Growth: DelveInsight Report Highlights 20% CAGR [City, State] – July 2, 2025 – The global sleep apnea market is projected to experience substantial acceleration, with an impressive Compound Annual Growth Rate (CAGR) of 20% anticipated during the study period of 2020-2034. This optimistic forecast comes from a comprehensive report … Read more

Ascletis® Pharmaceuticals Commences Phase IIa Study of Oral GLP-1R Agonist ASC30 in U.S. for Obesity and Overweight Patients [City, State] – July 2, 2025 – Ascletis Pharmaceuticals (HKEX: 1672), a leading biopharmaceutical company, today announced a significant milestone in its ongoing commitment to addressing metabolic diseases. The company has successfully dosed the first participants in … Read more

Neurizon Secures Global License with Elanco for NUZ-001, Ushering in a New Era for Animal Health [City, State] – July 2, 2025 – Neurizon, a pioneering biopharmaceutical company dedicated to advancing animal health, today announced a significant milestone with the signing of a global licensing agreement with Elanco Animal Health Incorporated (NYSE: ELAN), a global … Read more

Here’s an article about the Neurizon and Elanco licensing agreement: Neurizon Secures Global License with Elanco, Paving the Way for Accelerated Commercialization of NUZ-001 [City, State] – July 2, 2025 – Neurizon, a forward-thinking biopharmaceutical company dedicated to advancing novel therapeutic solutions, today announced a significant milestone: the signing of a global license agreement with … Read more

Lake Chelan Health Forges Strategic Partnership with Medline to Enhance Patient Care and Operational Efficiency CHELAN, WA – July 2, 2025 – Lake Chelan Health (LCH), a leading healthcare provider serving the Chelan Valley and surrounding communities, today announced it has entered into a comprehensive prime vendor agreement with Medline, a global manufacturer and distributor … Read more

Promising Advancement in Autoimmune Disease Treatment: Jacobio’s JAB-8263 Clears Regulatory Hurdle for Clinical Trials New York, NY – July 3, 2025 – Jacobio Pharmaceuticals, a clinical-stage biopharmaceutical company, announced today that its Investigational New Drug (IND) application for JAB-8263, a novel BET inhibitor, has been accepted by the U.S. Food and Drug Administration (FDA) for … Read more